Oxiris filter: how it removes cytokines and endotoxin in septic shock
Official title: Endotoxin and Cytokine Adsorption Properties of the Oxiris Hemofilter in Septic Shock: Evaluation of Saturation Phenomena and Inflammatory Mediators' Clearance Capacity
Run by Pauls Stradins Clinical University Hospital · NCT07419802 · Data updated 2026-11-12
This will test whether the Oxiris hemofilter keeps removing endotoxins and inflammatory proteins over 24 hours in adults with septic shock who need continuous kidney support.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 29 (estimated) |
| Sponsor | Pauls Stradins Clinical University Hospital Academic / other |
| Locations | 1 site (Riga) |
| Status | Recruiting |
| Started | March 1, 2026 |
| Main results expected | September 1, 2027 |
| Study ends | September 1, 2027 |
| Registry record updated | February 19, 2026 |
| Trial ID | NCT07419802 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18 years) with septic shock by Sepsis-3 criteria who require CVVH with an Oxiris (AN69-polyethylenimine) membrane for at least 24 hours and meet the study's dynamic scoring inclusion range are eligible.
✕Probably not a fit
Patients under 18, pregnant patients, those with contraindications to citrate anticoagulation, those expected to die within 24 hours from irreversible conditions, or those not treated with Oxiris CVVH are unlikely to benefit from participating.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, single-center observational study of adult patients with septic shock receiving continuous veno-venous hemofiltration (CVVH) with the AN69-polyethylenimine (Oxiris) membrane. Investigators will measure endotoxin and cytokine levels in blood and effluent over a continuous 24-hour treatment period to quantify membrane adsorption capacity and look for signs of saturation. The study will also quantify cytokine clearance by convective transport and examine whether changes in adsorption correlate with clinical course and outcomes. Data will provide in vivo time-course information on how the Oxiris membrane performs in routine ICU use.
Why it matters
Potential benefit: If successful, the results could guide optimal timing for Oxiris filter replacement to maintain toxin removal and possibly improve care for patients with septic shock.
How similar studies have gone: Oxiris is widely used and has some supporting laboratory and clinical reports, but in vivo quantitative data on adsorption saturation over time are limited and not well characterized.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria (should meet all the criteria mentioned below): * Septic shock patient with a Dynamic scoring system of 6-8 points /Septic shock definition based on Sepsis-3: a vasopressor requirement to maintain a mean arterial pressure of 65 mmHg or greater and serum lactate greater than 2mmol/L despite optimal (30ml/kg body weight) bolus fluid resuscitation/ * CVVH with AN69-polyethylenimine (Oxiris) membrane for at least 24 hours * Age \>18 years Exclusion Criteria: * Age \< 18 years * Pregnancy * Known contraindications to citrate anticoagulation * High likelihood of death within 24 hours due to irreversible comorbidities (e.g., end-stage cardiac, pulmonary, or hepatic disease; hepatorenal syndrome; advanced uncontrolled malignancy) * Simultaneous treatment with another adsorption device during the study period
Where it's running
-
Pauls Stradiņš Clinical University Hospital, Department of Anesthesiology and Reanimatology
Riga, Latvia Recruiting
Study contacts
- Study coordinator: Darja Smirnova, MD
- Email: darja.smirnova@rsu.lv
- Phone: +37126359852
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Non-invasive hemodynamic guidance for sepsis care on medical wards
This trial tests whether guiding fluid and vasopressor therapy for sepsis using non-invasive hemodynamic measurements works better than standard care.
-
Personalized Fluid Resuscitation in the Emergency Department
This pilot test checks if a quick, non-invasive stroke-volume assessment can help ED doctors tailor IV fluids for septic patients with low blood pressure.
-
Discordance between capillary refill time and oxygen use in septic shock
This study tests whether some septic shock patients can have a normal capillary refill time but still lack tissue oxygen use, to see if that mismatch relates to 28-day survival.
-
Targeting upper-normal magnesium to see if norepinephrine needs drop in septic shock
This trial tests whether keeping magnesium levels at the upper end of normal can reduce the amount and duration of norepinephrine needed in adults with septic shock.
-
Cortisol Levels and Mortality in Septic Shock ICU Patients
This study tests whether cortisol levels can predict death or recovery in adults with sepsis or septic shock in the ICU.
-
oXiris hemofilter use for adults with septic shock and kidney failure
This study tests whether using the oXiris hemofilter during continuous dialysis helps adults with septic shock and acute kidney injury survive and stabilize faster.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.